Cyanine3 amine
| Cat. # | Quantity | Price | Lead time | Buy this product |
|---|---|---|---|---|
| 110C0 | 1 mg | $125 | in stock | |
| 210C0 | 5 mg | $260 | in stock | |
| 410C0 | 25 mg |
$510
|
in stock | |
| 510C0 | 50 mg |
$895
|
in stock | |
| 610C0 | 100 mg |
$1490
|
in stock |
Cyanine3 amine is a functionalized cyanine dye containing a free amino group. Cyanine3 is an analog of Cy3®.
Amino group of this reagent can be conjugated with reactive groups such as NHS esters, carboxy groups (after carbodiimide activation), and epoxides.
The amino dye is supplied in salt form, and possesses some aqueous solubility.
Cyanine3 absorption and emission spectra
Customers also purchased with this product
Cyanine5 hydrazide
Cy5 hydrazide is a reactive dye for aldehydes and ketones. It can be used for the labeling of glycoproteins after periodate oxidation of sugar moieties.Cyanine7 tetrazine
Near infrared Cyanine7 dye derivative containing tetrazine group for TCO ligation.TAMRA azide, 5-isomer
Azide derivative of TAMRA fluorescent dye for сlick chemistry.General properties
| Appearance: | red powder |
| Molecular weight: | 627.73 |
| CAS number: | 2247688-56-6 |
| Molecular formula: | C36H52Cl2N4O |
| IUPAC name: | 3H-Indolium, 1-[6-[(6-aminohexyl)amino]-6-oxohexyl]-2-[3-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1-propen-1-yl]-3,3-dimethyl-, chloride, hydrochloride (1:1:1) |
| Solubility: | moderate solubility in water, good in polar organic solvents (DMF, DMSO, alcohols) |
| Quality control: | NMR 1H, HPLC-MS (95%) |
| Storage conditions: | Storage: 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light. Desiccate. |
| MSDS: | Download |
| Product specifications |
Spectral properties
| Excitation/absorption maximum, nm: | 555 |
| ε, L⋅mol−1⋅cm−1: | 150000 |
| Emission maximum, nm: | 570 |
| Fluorescence quantum yield: | 0.31 |
| CF260: | 0.04 |
| CF280: | 0.09 |
Product citations
- Gorshkova, M.; Vanchugova, L.; Osipova, N.; Nikitin, A.; Kotova, J.; Kovalenko, E.; Ermolenko, Y.; Malinovskaya, J.; Kovshova, T.; Gelperina, S. Hybrid DIVEMA/PLGA nanoparticles as the potential drug delivery system. Research Square, 2024, preprint. doi: 10.21203/rs.3.rs-4594368/v1
- Ruan, Z.; Li, S.; Grigoropoulos, A.; Amiri, H.; Hilburg, S. L.; Chen, H.; Jayapurna, I.; Jiang, T.; Gu, Z.; Alexander-Katz, A.; Bustamante, C.; Huang, H.; Xu, T. Population-Based Heteropolymer Design to Mimic Protein Mixtures. Nature, 2023, 615(7951), 251–258. doi: 10.1038/s41586-022-05675-0
- Nizamov, T. R.; Iliasov, A. R.; Vodopyanov, S. S.; Kozhina, I. V.; Bordyuzhin, I. G.; Zhukov, D. G.; Ivanova, A. V.; Permyakova, E. S.; Mogilnikov, P. S.; Vishnevskiy, D. A.; Shchetinin, I. V.; Abakumov, M. A.; Savchenko, A. G. Study of Cytotoxicity and Internalization of Redox-Responsive Iron Oxide Nanoparticles on PC-3 and 4T1 Cancer Cell Lines. Pharmaceutics, 2023, 15(1), 127. doi: 10.3390/pharmaceutics15010127
- Malinovskaya, J.; Salami, R.; Valikhov, M.; Vadekhina, V.; Semyonkin, A.; Semkina, A.; Abakumov, M.; Harel, Y.; Levy, E.; Levin, T.; Persky, R.; Chekhonin, V.; Lellouche, J.-P.; Melnikov, P.; Gelperina, S. Supermagnetic Human Serum Albumin (HSA) Nanoparticles and PLGA-Based Doxorubicin Nanoformulation: A Duet for Selective Nanotherapy. International Journal of Molecular Sciences, 2023, 24(1), 627. doi: 10.3390/ijms24010627
Cy® is a trademark of GE Healthcare.
The count of items is incorrect.
Your cart is empty
$ 
